Annalisa Relini

Annalisa Relini

Auto-generated profile, based on publicly available information

Annalisa Relini

Physics Department, University of Genoa

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
MCMarta Campora
Marta Campora
CCClaudio Canale
Claudio Canale
EGElena Gatta
Elena Gatta
BTBruno Tasso
Bruno Tasso
ELErik Laurini
Erik Laurini
Michele TonelliMichele Tonelli
Michele Tonelli
Two series of naphthoquinone and anthraquinone derivatives decorated with an aromatic/heteroaromatic chain have been synthesized and evaluated as potential promiscuous agents capable of targeting different factors playing a key role in Alzheimer’s disease (AD) pathogenesis. On the basis of the in vitro biological profiling, most of them exhibited a significant ability to inhibit amyloid aggregation, PHF6 tau sequence aggregation, acetylcholinesterase (AChE), and monoamine oxidase (MAO) B. In particular, naphthoquinone 2 resulted as one of the best performing multitarget-directed ligand (MTDL) experiencing a high potency profile in inhibiting β-amyloid (Aβ40) aggregation (IC50 = 3.2 μM), PHF6 tau fragment (91% at 10 μM), AChE enzyme (IC50 = 9.2 μM) jointly with a remarkable inhibitory activity against MAO B (IC50 = 7.7 nM). Molecular modeling studies explained the structure–activity relationship (SAR) around the binding modes of representative compound 2 in complex with hMAO B and hAChE enzymes, revealing inhibitor/protein key contacts and the likely molecular rationale for enzyme selectivity. Compound 2 was also demonstrated to be a strong inhibitor of Aβ42 aggregation, with potency comparable to quercetin. Accordingly, atomic force microscopy (AFM) revealed that the most promising naphthoquinones 2 and 5 and anthraquinones 11 and 12 were able to impair Aβ42 fibrillation, deconstructing the morphologies of its fibrillar aggregates. Moreover, the same compounds exerted a moderate neuroprotective effect against Aβ42 toxicity in primary cultures of cerebellar granule cells. Therefore, our findings demonstrate that these molecules may represent valuable chemotypes toward the development of promising candidates for AD therapy.

1 April 2010 in Biophysical Journal
Verified
Journal Article
Closed access
ARAnnalisa Relini
Annalisa Relini
STSilvia Torrassa
Silvia Torrassa
RFRiccardo Ferrando
Riccardo Ferrando
RRRanieri Rolandi
Ranieri Rolandi
SCSilvia Campioni
Silvia Campioni
AGAlessandra Gliozzi
Alessandra Gliozzi

9 August 2018 in Small
Verified
Journal Article
Closed access
PDF file
CDCristiano D'Andrea
Cristiano D'Andrea
AFAntonino Foti
Antonino Foti
MCMaximilien Cottat
Maximilien Cottat
MBMartina Banchelli
Martina Banchelli
CCClaudia Capitini
Claudia Capitini
PMPaolo Matteini
Paolo Matteini

27 December 2013 in Biomolecules
Verified
Journal Article
Open access
PDF file
ARAnnalisa Relini
Annalisa Relini
NMNadia Marano
Nadia Marano
AGAlessandra Gliozzi
Alessandra Gliozzi
In this paper, we discuss amyloidogenic proteins, their misfolding, resulting structures, and interactions with membranes, which lead to membrane damage and subsequent cell death. Many of these proteins are implicated in serious illnesses such as Alzheimer’s disease and Parkinson’s disease. Misfolding of amyloidogenic proteins leads to the formation of polymorphic oligomers and fibrils. Oligomeric aggregates are widely thought to be the toxic species, however, fibrils also play a role in membrane damage. We focus on the structure of these aggregates and their interactions with model membranes. Study of interactions of amlyoidogenic proteins with model and natural membranes has shown the importance of the lipid bilayer in protein misfolding and aggregation and has led to the development of several models for membrane permeabilization by the resulting amyloid aggregates. We discuss several of these models: formation of structured pores by misfolded amyloidogenic proteins, extraction of lipids, interactions with receptors in biological membranes, and membrane destabilization by amyloid aggregates perhaps analogous to that caused by antimicrobial peptides.

17 September 2020 in Nanoscale
Verified
Journal Article
Open access
PDF file
Ester CanepaEster Canepa
Ester Canepa
SSSebastian Salassi
Sebastian Salassi
AMAnna Lucia de Marco
Anna Lucia de Marco
CLChiara Lambruschini
Chiara Lambruschini
DODavide Odino
Davide Odino
ARAnnalisa Relini
Annalisa Relini
Experiments and simulations reveal that amphiphilic nanoparticles suppress phase separation in neuronal-like lipid bilayers and form bilayer-embedded ordered aggregates.

1 September 2021 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Open access
Ester CanepaEster Canepa
Ester Canepa
DBDavide Bochicchio
Davide Bochicchio
MGMatteo Gasbarri
Matteo Gasbarri
DODavide Odino
Davide Odino
CCClaudio Canale
Claudio Canale
ARAnnalisa Relini
Annalisa Relini
Plasma membranes represent pharmacokinetic barriers for the passive transport of site-specific drugs within cells. When engineered nanoparticles (NPs) are considered as transmembrane drug carriers, the plasma membrane composition can affect passive NP internalization in many ways. Among these, cholesterol-regulated membrane fluidity is probably one of the most biologically relevant. Herein, we consider small (2–5 nm in core diameter) amphiphilic gold NPs capable of spontaneously and nondisruptively entering the lipid bilayer of plasma membranes. We study their incorporation into model 1,2-dioleoyl-sn-glycero-3-phosphocholine membranes with increasing cholesterol content. We combine dissipative quartz crystal microbalance experiments, atomic force microscopy, and molecular dynamics simulations to show that membrane cholesterol, at biologically relevant concentrations, hinders the molecular mechanism for passive NP penetration within fluid bilayers, resulting in a dramatic reduction in the amount of NP incorporated.